What drove today’s gain in SHLTN.SW stock?

Volume jumped to **78,716** and the share price rose to **CHF 1.18**, driven by short-term momentum and renewed interest in telemedicine partnerships and device rollouts.

What is Meyka AI’s outlook for SHLTN.SW stock?

Meyka AI's model shows a quarterly target **CHF 1.34** (+13.56%) from **CHF 1.18** today, with a 12-month projection near **CHF 1.11** that signals longer-term risk.

Is SHLTN.SW stock undervalued versus peers?

By Price/Sales, SHL’s **0.40** compares with Healthcare sector average **2.49**, suggesting a valuation gap, but negative margins and liquidity concerns justify a discount.

What are the main risks for SHLTN.SW stock?

Key risks include negative earnings (**EPS -0.76**), current ratio below 1 (**0.87**), thin daily liquidity and execution risk converting clinical partnerships into recurring revenue.

CH Stocks

SHL Telemedicine (SHLTN.SW) up 7.11% to CHF1.18 on SIX 06 Jan 2026: momentum

ByHuzaifa Zahoor January 7, 2026January 7, 2026

SHLTN.SW stock jumped 7.11% to CHF 1.18 on the SIX at market close on 06 Jan 2026, making SHL Telemedicine one of today’s top gainers in Swiss healthcare. Trading volume of 78,716 shares exceeded the 50-day average, driven by short-term momentum and renewed investor focus on telemedicine device contracts. We examine why the market moved, the company’s valuation and the risk profile for investors tracking SHL Telemedicine Ltd. (SHLTN.SW). Meyka AI-powered market analysis highlights technical drivers plus a model forecast to guide short-term price expectations.